POAI News and Press, Predictive Oncology Inc. From 03/31/22

Predictive Oncology press release (NASDAQ:POAI): FY GAAP EPS of -$0.36 misses by $0.12. Revenue of $1.42M (+13.6% Y/Y) misses by $2M. Shares -2.66% AH. For further details see: Predictive Oncology GAAP EPS of -$0.36 misses by $0.12, revenue of $1.42M misses by $2M

EAGAN, Minn., March 31, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the year ended Decembe...

Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had reached a key milestone toward monetizing its unique approach to leverage AI in oncology drug d...

MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) achieved a key milestone toward monetizing its unique approach to leverage artificial intelligence (AI) in oncology drug discovery. Earlier this year, Predictive Oncology’s Discovery 21 proof-of-concep...

Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is focused on establishing a position as a first mover in the artificial intelligence (“AI”)-powered, d...

MINNEAPOLIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that POAI expects will grow to $20 billion in the next three years, reported the Company today in outlining its...

Point Roberts, WA and Vancouver, BC - January 14, 2022 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com ), a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye - watching stock news, deal tracker and advan...

Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today reported the preliminary results of its Discovery 2021 program. According to the update, Predictive Oncologyȁ...

MINNEAPOLIS, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary’s evaluation demonstrated their proprietary Artificial Intelligence (AI) program CoRE&#...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’ll begin this penny stock list in the same manner that I begin all lists of penny stocks: With a caveat. Penny stocks are among the most volatile classes of investments. Pretty much everyone interested in this...